- Home
- PHAR vs ABL Comparison
PHAR vs ABL Comparison
Compare PHAR & ABL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- ABL
- Stock Information
- Founded
- PHAR 1988
- ABL 2004
- Country
- PHAR Netherlands
- ABL United States
- Employees
- PHAR N/A
- ABL N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- ABL Investment Managers
- Sector
- PHAR Health Care
- ABL Finance
- Exchange
- PHAR Nasdaq
- ABL Nasdaq
- Market Cap
- PHAR 627.5M
- ABL 727.7M
- IPO Year
- PHAR N/A
- ABL N/A
- Fundamental
- Price
- PHAR $9.98
- ABL $7.45
- Analyst Decision
- PHAR Strong Buy
- ABL Strong Buy
- Analyst Count
- PHAR 3
- ABL 4
- Target Price
- PHAR $27.00
- ABL $13.88
- AVG Volume (30 Days)
- PHAR 6.0K
- ABL 234.4K
- Earning Date
- PHAR 03-13-2025
- ABL 11-07-2024
- Dividend Yield
- PHAR N/A
- ABL N/A
- EPS Growth
- PHAR N/A
- ABL N/A
- EPS
- PHAR N/A
- ABL N/A
- Revenue
- PHAR $285,745,000.00
- ABL $102,407,324.00
- Revenue This Year
- PHAR $20.08
- ABL $70.90
- Revenue Next Year
- PHAR $9.22
- ABL $65.20
- P/E Ratio
- PHAR N/A
- ABL N/A
- Revenue Growth
- PHAR 30.64
- ABL 77.68
- 52 Week Low
- PHAR $6.65
- ABL $6.75
- 52 Week High
- PHAR $13.20
- ABL $13.25
- Technical
- Relative Strength Index (RSI)
- PHAR 56.13
- ABL 45.15
- Support Level
- PHAR $9.37
- ABL $6.75
- Resistance Level
- PHAR $10.15
- ABL $7.65
- Average True Range (ATR)
- PHAR 0.50
- ABL 0.35
- MACD
- PHAR -0.09
- ABL 0.01
- Stochastic Oscillator
- PHAR 57.53
- ABL 54.69
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About ABL Abacus Life Inc.
Abacus Life Inc is a vertically integrated alternative asset manager specializing in investing in life insurance products throughout the lifecycle of a life insurance policy.